

## 4DMedical wins industry partners and discussed in US Congress

**10 April 2025**

### Highlights

- Two new contracts with industry partners for 4DMedical imaging technology to support:
  - SMS Biotech in their Phase 1 trial for stem cell therapy for treatment of COPD; and
  - a multinational lung device developer for clinical trial of novel lung implantable device
- 4DMedical technology highlighted during Congressional Testimony on VA Healthcare Modernization

---

**Melbourne, Australia, 10 April 2025:** Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today announces that it has been selected by two separate industry partners to provide its ground-breaking lung imaging technology to support bringing new lung disease therapies to market. The Company is also pleased to have been referenced by Philips in Congressional Testimony on VA Healthcare Modernization.

### 4DMedical selected by SMS Biotech for groundbreaking COPD clinical trial

SMS Biotech, a San Diego based biotech company that has discovered a novel human stem cell, has chosen 4DMedical for its unique suite of software tools capable of providing both structural and functional analysis of the lungs, including CT:VQ™ perfusion assessment. 4DMedical’s technology will play a critical role in the trial, assessing baseline lung health before therapy, and subsequently tracking changes in lung function and structure post-therapy, to quantify the impact of the SMS stem cells.

SMS Biotech is beginning the next phase of its journey to reverse the effects of COPD, a disease impacting millions globally. The quantification of the expected results relies not only on 4DMedical technology to document the structural improvements in lung health, but also to demonstrate how air movement within the lungs has improved due to these changes.

The trial, recently cleared by the Australian Government, will test the therapy in a cohort of mild to moderate COPD patients, marking a significant milestone in regenerative medicine, with scanning performed at Cabrini Health. The initial contract value is US\$40k to provide 42 quantitative assessments for the first cohort of patients throughout their course of treatment. SMS Biotech is currently pursuing ‘compassionate-use’ with several US Academic Medical Centers prior to formal stage approvals. As clinical trials progress through to regulatory clearances, the quantum of these contracts to supply quantitative assessment will also scale, with the ultimate position being recognised as the companion imaging biomarker for their therapy, and similar opportunities across the pharmaceutical and device sectors more broadly.

### 4DMedical supports additional medical device company clinical trial

In addition, a medical device developer, who has requested to remain un-named, specialising in respiratory health has also contracted to utilise 4DMedical’s technology to enhance their evaluation process for clinical trial candidates. This company’s advanced devices, aimed at diagnosing and treating complex lung conditions, will leverage 4DMedical’s imaging and functional analysis tools to provide precise assessments of lung function and structure. By integrating 4DMedical’s capabilities, they aim to better identify suitable trial participants and track key respiratory metrics, ultimately advancing their ability to address a range of



pulmonary conditions. This relationship highlights the versatility and growing adoption of 4DMedical's technology within the respiratory health sector.

Collaboration with global companies developing treatment for lung disease forms an integral part of 4DMedical's commercialisation strategy. It represents a large addressable market, as pharmaceutical and device companies are increasingly seeking imaging biomarkers to support their development into clinical care, or to shorten their clinical trials through more appropriate patient selection. These collaborations underscore 4DMedical's growing reputation as an industry partner for advancing respiratory care for patients with chronic lung diseases.

The Company confirms that the identity of the medical device developer is not material and that the announcement contains all material information relevant to the contract.



Figure 1: Extract from investor presentation highlighting core commercialisation strategy which includes supporting industry partnerships, such as Pharmaceutical and Device companies.

## 4DMedical highlighted by Philips as a solution during Congressional Testimony on VA Healthcare Modernization

Jeff DiLullo, Executive Vice President and Chief Executive Officer, Philips North America, testified (on behalf of Philips) at the United States House of Representatives Committee on Veterans' Affairs. The statement included the following wording:

'Acknowledging the need for faster, affordable, and less invasive ways to identify and diagnose lung disease, Philips, in concert with our partner, 4DMedical, innovated an FDA-cleared cardiopulmonary software that can transform standard CT imaging into a detailed four-dimensional image. This advanced technology allows VA clinicians to better assess pulmonary function and leads to faster diagnoses and less invasive procedures. By leveraging this four-dimensional lung screening, VA can improve health outcomes for veterans and reduce dependency on taxpayer resources.

This innovation empowers clinicians by providing tools to quickly assess lung health and prioritize those needing specialized care. Philips, in partnership with 4DMedical, is committed to transforming the way we diagnose and treat respiratory conditions in veterans.



The platform plays a key role in aiding clinicians in the diagnosis, particularly for veterans, helping with the early detection of conditions like chronic obstructive pulmonary disease (COPD), deployment-related respiratory disease (DRRD), interstitial lung disease (ILD), asthma, pulmonary fibrosis, and lung cancer.

This non-invasive approach reduces costs associated with unnecessary procedures, accelerates diagnosis and expedites treatment, significantly enhancing the overall patient experience. The impact is so profound, we have heard stories of veterans seeking out this technology on their own, outside of VA provided care, and at their own personal expense. For instance, a case involving a 41-year-old veteran with a history of deployment to Iraq showcased how the four-dimensional scan provided critical insights after nearly two decades of inconclusive testing, validating symptoms and confirming a likely diagnosis of DRRD without invasive procedures.

By embracing advancements like this four-dimensional lung screening, utilizing the Philips CT, we are exemplifying the textbook definition of modernizing healthcare at the VA and leaning into the future – all for the benefit of our nation’s veterans. We must continue to champion these technologies to ensure that every veteran receives the timely and effective care they rightfully deserve.’

Video of the session can be found [here](#), while the full written statement is available [here](#).

#### **4DMedical MD/CEO and Founder Andreas Fouras said:**

*Our partnership with SMS Biotech, and other industry innovation leaders, highlights the growing demand for 4DMedical’s imaging technology. By providing precise structural imaging and rich functional insights, we are accelerating success for our industry partners in their quest to bring novel and powerful treatments to market. As these treatments progress towards market entry, 4DMedical stands ready to continue to support that effort through providing our technology to larger and larger clinical trials. These successes will serve to continue to grow our reputation in this multibillion-dollar sector.*

*We thank the leadership of Philips for their efforts last week in addressing the House Committee highlighting how 4DMedical technologies could assist the VA to efficiently triage Veterans, aiding them to diagnose deployment-related respiratory diseases faster and more cost effectively.*

**–ENDS–**

Authorised by the 4DMedical Board of Directors.

#### **Contacts**

##### **Corporate**

Investor Relations

[investor.relations@4dmedical.com](mailto:investor.relations@4dmedical.com)

##### **Administration**

Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

##### **Media Enquiries**

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

#### **About 4DMedical**

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.



At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)